Granza Bio
Building programmable therapeutics for the immune system
About
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.
Topics
- Location
- San Francisco, CA, United States
- Team size
- 8 employees
- YC batch
- Winter 2024
- Status
- Active
- Stage
- Early stage
